argenx SE Sponsored ADR ARGX 深 沪
等待开盘 06-26 09:30:00 美东时间
889.08
+36.580
+4.29%
华盛通- 最 高933.99
- 今 开862.82
- 成交量 44.64万股
- 最 低 837.74
- 昨 收 852.50
- 总市值 4822.25万
- 52周最高 934.6199
- 市盈率 静 --
- 换手率 823.03%
- 52周最低 536.30
- 委 比 78.41%
- 总股本 5.42万
- 历史最高 934.6199
- 量 比 0.96
- 振 幅 11.29%
- 历史最低 1.10
- 每 手 1
- 风险率 98.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study
HC Wainwright sees over $1 billion in sales potential for Argenx's Vyvgart in IMNM despite myositis trial changes.
今天 01:57
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position: Analyst
Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read the market & analyst reaction.
06-11 21:09
Forecasting The Future: 16 Analyst Projections For argenx
Ratings for argenx (NASDAQ:ARGX) were provided by 16 analysts in the past three...
03-10 03:01
Argenx Touts Positive Phase 3 Eye Disease Study Results
Argenx reports positive Phase 3 results for Vyvgart in eye disease, beats earnings as sales surge over 70%.
02-26 22:01
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
argenx Highlights 2026 Strategic Priorities As Q4 Sales Reach $1.29B And Preliminary 2025 Net Sales Total $4.15B
Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter salesVYVGART impact continues with approximately 19,000 patients on
01-12 14:32
Baird Downgrades argenx to Neutral, Lowers Price Target to $858
Baird analyst Colleen Kusy downgrades argenx (NASDAQ:ARGX) from Outperform to Neutral and lowers the price target from $924 to $858.
2025-12-18 19:01
Argenx, Navan And 3 Stocks To Watch Heading Into Monday
Stock futures up, focus on HYFT, ARGX, NAVN, AXR, CSBR as they report earnings. Top 2 energy stocks to watch for potential plunge this month.
2025-12-15 15:42
Wolfe Research Downgrades argenx to Peer Perform
Wolfe Research analyst Andy Chen downgrades argenx (NASDAQ:ARGX) from Outperform to Peer Perform.
2025-11-24 19:00
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
VYVGART® SC, a groundbreaking IgG Fc-antibody fragment targeting FcRn, has been approved in Europe for CIDP treatment. Based on the ADHERE trial, this novel therapy offers significant clinical improvement and reduced relapse risk, marking a major advancement for CIDP patients after over 30 years of limited treatment options.
2025-06-20 17:00
